Cambrex Announces Investment & Expansion
Cambrex, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has announced a SEK 72 million ($9 million) investment to expand large scale manufacturing capacity at its Karlskoga facility in Sweden.
The investment includes the installation of new multi-purpose reactors ranging from 4m3 to 12m3 and upgrading of the control room within an existing plant on site. The new facilities will undergo validation and cGMP qualification ahead of the operational startup in Q4 2016. This extra capacity increases the large scale manufacturing capabilities of the Karlskoga facility, which supports clients’ development projects from R&D through to large scale commercial manufacturing.
“Our facility at Karlskoga is strategically important, both in Scandinavia and the wider European markets, and this investment is in response to an increase in demand for larger scale, multi-purpose manufacturing capabilities,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga. “By creating greater capacity within the current infrastructure, we have combined expansion and efficiency at the site, both of which will benefit our customers.”
The expansion at Cambrex’s Swedish site is part of an ongoing strategic campaign to invest in small molecule API manufacturing across its global network of facilities.
Visit Cambrex at CPhI Hall 8.1, Stand 8F30
Meet the experts you’ll enjoy working with at CPhI, where we’ll be unveiling the new Cambrex brand.
Contact Cambrex
Twitter: @cambrex
LinkedIn: cambrex
www.cambrex.com
most read
The Future of Demand for Chemicals
The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.
Substances of Concern
The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.
Pharma Outlook 2025
The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.
“Access to Talent is a Crucial Factor”
In an interview with CHEManager, Edgardo Hernandez, President of Lilly Manufacturing, explains the strategy behind the ambitious investment project.
Specialty Chemicals in a Shifting World
Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.